Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026
Odyssey Therapeutics will present the design of a Phase 2a trial of OD-001 combined with vedolizumab in moderate-to-severe ulcerative colitis at the ACG 2026 annual meeting. The randomized, double-blind study plans to enroll up to 146 patients, testing a 12-week combination induction followed by OD-001 monotherapy maintenance through Week 52.
Key figures
- Drug Name
- OD-001
- Phase Of Trial
- Phase 2a
- Topline timing
- second half of 2027
- Induction period
- 12-week induction, maintenance through Week 52
- Planned enrollment
- up to 146 patients
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.